Articles by Date (Latest First)

   Filter by author: Aly W. | Lain M. | Sam S. | Mitzi

• Puberty Blockers: A Review of GnRH Analogues in Transgender Youth (Mitzi, January 2022)

• An Interactive Web Simulator for Estradiol Levels with Injectable Estradiol Esters (Aly W., July 2021)

• An Informal Meta-Analysis of Estradiol Curves with Injectable Estradiol Preparations (Aly W., July 2021)

• An Exploration of Sublingual Estradiol as an Alternative to Oral Estradiol in Transfeminine People (Sam S., June 2021)

• Clinical Guidelines with Information on Transfeminine Hormone Therapy (Aly W., November 2020)

• Estrogens and Their Influences on Coagulation and Risk of Blood Clots (Aly W., October 2020)

• Announcing Transfeminine Science—A Site for Information on Transfeminine Hormone Therapy (Aly W., October 2020)

• Prenatal Diethylstilbestrol Exposure and Likelihood of Being Transgender (Aly W., July 2020)

• The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy (Aly W., July 2020)

• Commentary of a New Study of Prostate Cancer Incidence in Transfeminine People Receiving Hormone Therapy (Sam S., July 2020)

• Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy (Aly W., July 2020)

• Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy (Aly W., July 2020)

• Injectable Estradiol Formulations Available for Transfeminine People in the United States (Aly W., June 2020)

• On Changes in Bone Shape in Transfeminine Individuals Under Gender-Affirming Hormone Therapy (Lain M., May 2020)

• Hormone Levels During Normal Puberty in Cisgender Girls (Aly W., April 2020)

• Literature Excerpts on Spironolactone and Hormone Levels in Cisgender Women (Aly W., April 2020)

• Breast Cancer Risk with Hormone Therapy in Transfeminine People (Aly W., April 2020)

• Supplement: Breast Cancer Risk with Hormone Therapy in Transfeminine People (Aly W., April 2020)

• Recent Developments on Cyproterone Acetate and Meningioma Risk Out of France and Implications for Transfeminine People (Aly W., April 2020)

• Approximate Comparable Dosages of Estradiol by Different Routes (Aly W., April 2020)

• Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy (Sam S., April 2020)

• Oral versus Transdermal Estradiol in Feminising Hormone Therapy for Transgender Individuals (Sam S., April 2020)

• Excerpts: Reviews, Cohort Studies and Randomised Controlled Trials Comparing the Feminising Efficacy of Estradiol Administered by Oral and Non-Oral Routes (Sam S., April 2020)

• Analysis of Cardiovascular and Thromboembolic Toxicity with High Dose Parenteral Polyestradiol Phosphate in the Treatment of Prostate Cancer (Sam S., April 2020)

• Dose-Ranging Data on Estradiol Patches and Testosterone Suppression in Men Based on de Ronde et al. (2009) (Aly W., April 2020)

• Discussion on Women with Complete Androgen Insensitivity Syndrome, Breast Development, and Progesterone (Aly W., March 2020)

• Nandrolone as an Alternative Androgen with Reduced Androgenic Side Effects for Transfeminine and Transmasculine People (Aly W., March 2020)

• Excerpts: Guidance for Prolactin Monitoring and Elevated Prolactin Levels in Transfeminine People (Aly W., March 2020)

• Progestogens and Breast Cancer in Transgender Women: A Review and Discussion of Risk (Sam S., February 2020)

• Progesterone and its Role in Breast Development During Female Puberty (Aly W., February 2020)

• The Roles of Placebo and Nocebo in Medication Effects and Why Subjective Reports Are Unreliable (Aly W., January 2020)

• The Influence of Progesterone and Other Progestogens on Sexual Desire and Function (Aly W., January 2020)

• A Drospirenone Progestogen-Only Birth Control Pill (Slynd) Has Been Introduced in the United States and Europe: Potential Use in Transfeminine Hormone Therapy (Aly W., December 2019)

• A Review of Selective Estrogen Receptor Modulators and their Potential for Transfeminine Hormone Therapy (Lain M., October 2019)

• Sources/Excerpts: A Review of Selective Estrogen Receptor Modulators and their Potential for Transfeminine Hormone Therapy (Lain M., October 2019)

• Sources/Excerpts: On the Impact of Sex Hormones on Fat Metabolism with an Eye Towards Transfeminine Hormone Therapy (Lain M., September 2019)

• On the Impact of Sex Hormones on Fat Metabolism with an Eye Towards Transfeminine Hormone Therapy (Lain M., September 2019)

• Darolutamide (Nubeqa), a New Second-Generation Nonsteroidal Antiandrogen, Has Been Approved for Medical Use (Aly W., September 2019)

• Collected Links and Excerpts on the Role of Growth Hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) in Breast Development (Aly W., August 2019)

• Commentary and Fact Check of Dr. Will Powers’s Transgender Care Presentation (Aly W., August 2019)

• The Relationship Between the Endocrine System and Muscle Mass (Lain M., August 2019)

• Excerpts: Early Progestogen Exposure May Result in Suboptimal Breast Development (Aly W., July 2019)

• Published Literature on Bicalutamide as an Antiandrogen for Transfeminine People (Aly W., July 2019)

• Low Doses of Cyproterone Acetate Are Maximally Effective for Testosterone Suppression in Transfeminine People (Aly W., July 2019)

• Data Show That the Number of People Hormonally Transitioning has Skyrocketed in Recent Years (Aly W., July 2019)

• A Review of Studies on Estradiol Levels and Testosterone Suppression with High-Dose Transdermal Estradiol Gel and Ointment in Cisgender Men with Prostate Cancer (Aly W., June 2019)

• Analysis of Sublingual Estradiol and Medroxyprogesterone Acetate (MPA) in Transfeminine People Based on Jain et al. (2019) and Deutsch et al. (2015) (Aly W., June 2019)

• Injectable Aqueous Suspensions of Sex Hormones and How Depot Injectables Work (Aly W., June 2019)

• An Exploration of Possibilities for Hormone Therapy in Non-Binary Transfeminine People (Aly W., June 2019)

• Discussion on Cyproterone Acetate and Risk of Depression (Aly W., March 2019)

• Genital Application via the Scrotum and Neolabia for Greatly Enhanced Absorption of Transdermal Estradiol in Transfeminine People (Aly W., March 2019)

• Analysis of Estradiol and Testosterone Levels with Oral Estradiol in Transfeminine People Based on Leinung et al. (2018) (Aly W., March 2019)

• Published Case Reports of Lactation and/or Breastfeeding in Transfeminine People (Aly W., March 2019)

• Commentary and Fact Check of Dr. Jerilynn Prior’s 2019 Review on Progesterone for Transfeminine People (Aly W., March 2019)

• Discussion on Bicalutamide Dosage in Transfeminine People (Aly W., March 2019)

• Approval of Relugolix (Relumina), the Second Orally Active GnRH Antagonist, and Relevance for Transfeminine People (Aly W., February 2019)

• Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People (Aly W., January 2019)

• Administration of Oral Progesterone Capsules Rectally Instead of Orally for Greatly Improved Efficacy in Transfeminine People (Aly W., December 2018)

• A Review of Studies on Spironolactone and Testosterone Levels in Cisgender Men and Transfeminine People (Aly W., December 2018)

• Bicalutamide: Frequently Asked Questions and Common Misconceptions (Aly W., December 2018)

• Information on Bicalutamide (Casodex) as an Antiandrogen for Transfeminine People (Aly W., September 2018)

• How to Research Transfeminine Hormone Therapy in the Academic Literature and Obtain Papers (Aly W., September 2018)

• Buserelin, a Gonadotropin-Releasing Hormone Agonist, is Inexpensively Available as a Nasal Spray From Online Pharmacies (Aly W., August 2018)

• Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects (Aly W., August 2018)

• Sources/Excerpts: Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects (Aly W., August 2018)

• An Introduction to Hormone Therapy for Transfeminine People (Aly W., August 2018)

• EC508 (Estradiol Aminosulfonylbenzoylproline), a Unique and Highly Promising Estradiol Ester and Possible Oral Estradiol Form of the Future (Aly W., August 2018)

• Approval of Elagolix (Orilissa), the first Orally Active Gonadotropin-Releasing Hormone Antagonist, and Relevance for Transfeminine People (Aly W., August 2018)